ALPMY Projected Dividend Yield
ADR/Astellas Pharma Inc ( OTCBB : ALPMY )Astellas Pharma is mainly engaged in the research and development, manufacture, and sale of pharmaceuticals globally. Co.'s main products include XTANDI, Prograf, Betanis/Myrbetriq/BETMIGA, XOSPATA, Evrenzo, PADCEV, and other. XTANDI is an androgen receptor signaling inhibitor indicated for the treatment of forms of advanced prostate cancer. Betanis/Myrbetriq/BETMIGA is for Overactive Bladder (OAB) treatment, a beta-3 adrenergic receptor agonist. XOSPATA is a FLT3 inhibitor for adult patients with relapsed or refractory Acute Myeloid Leukemia (AML) with a FLT3 mutation-positive. PADCEV (enfortumab vedotin) is a treatment for patients with locally advanced or metastatic urothelial cancer. 25 YEAR PERFORMANCE RESULTS |
ALPMY Dividend History Detail ALPMY Dividend News ALPMY Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
2024 |
N/A |
N/A |
Sep 30, 2024 |
Dec 17, 2024 |
0.2467 |
2024 |
N/A |
N/A |
Mar 28, 2024 |
Jun 17, 2024 |
0.2242 |
2024 Total: |
0.4709 |
||||
2023 |
N/A |
N/A |
Sep 29, 2023 |
Dec 18, 2023 |
0.2365 |
2023 |
N/A |
N/A |
Mar 31, 2023 |
Jun 16, 2023 |
0.2162 |
2023 Total: |
0.4527 |
||||
2022 |
N/A |
N/A |
Sep 30, 2022 |
Dec 15, 2022 |
0.2202 |
2022 |
N/A |
N/A |
Mar 30, 2022 |
Jun 15, 2022 |
0.1934 |
2022 Total: |
0.4136 |
||||
2021 |
N/A |
N/A |
Sep 29, 2021 |
Dec 16, 2021 |
0.2204 |
2021 |
N/A |
N/A |
Mar 30, 2021 |
Jun 16, 2021 |
0.1919 |
2021 Total: |
0.4124 |
||||
2020 |
N/A |
N/A |
Sep 29, 2020 |
Dec 15, 2020 |
0.2011 |
2020 |
N/A |
N/A |
Mar 30, 2020 |
Jun 15, 2020 |
0.1862 |
2020 Total: |
0.3873 |
||||
2019 |
N/A |
N/A |
Sep 27, 2019 |
Dec 17, 2019 |
0.1843 |
2019 |
N/A |
N/A |
Mar 29, 2019 |
Jul 05, 2019 |
0.1752 |
2019 Total: |
0.3595 |